{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:08:35Z","timestamp":1740460115137,"version":"3.37.3"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2021,6,14]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary rehabilitation causes short-term improvement in exercise capacity, dyspnoea and health-related quality of life in idiopathic pulmonary fibrosis (IPF); however, long-term maintenance of the improvement is difficult. Nintedanib, an antifibrotic drug, has been shown to delay the worsening of pulmonary function in IPF. Therefore, the concomitant use of nintedanib with pulmonary rehabilitation is anticipated to contribute to the long-term maintenance of the pulmonary rehabilitation effects. The long-term effect of pulmonary rehabilitation under nintedanib treatment in IPF (FITNESS) study is a multicenter, randomised, prospective, parallel-group, open-label trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study will enrol 84 patients with IPF who have been treated with nintedanib. Patients in the pulmonary rehabilitation group will receive a programmed short-term induction pulmonary rehabilitation programme, followed by a maintenance home-based pulmonary rehabilitation programme, while patients in the control group will receive usual outpatient care. Patients in both groups will continue to receive nintedanib treatment throughout the study period. The primary end-point of the study is to compare the change in the 6-min walk distance from the baseline to 12\u2005months between the pulmonary rehabilitation and control groups. The main secondary end-point is endurance exercise time, measured using a bicycle ergometer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>FITNESS is the first randomised controlled study to evaluate the long-term effects of pulmonary rehabilitation in IPF treated with nintedanib. This study will address the hypothesis that concomitant use of nintedanib contributes to the maintenance of long-term effects of pulmonary rehabilitation, thus leading to a comprehensive therapeutic approach of \u201cnintedanib and pulmonary rehabilitation\u201d in the antifibrotic era.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00321-2021","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T16:10:18Z","timestamp":1624637418000},"page":"00321-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis"],"prefix":"10.1183","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-9605","authenticated-orcid":false,"given":"Osamu","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-9510","authenticated-orcid":false,"given":"Shinichi","family":"Arizono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Morino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-7484","authenticated-orcid":false,"given":"Koichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-5459","authenticated-orcid":false,"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2024101711145708000_7.3.00321-2021.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2024101711145708000_7.3.00321-2021.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0566OC"},{"key":"2024101711145708000_7.3.00321-2021.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01592-2016"},{"key":"2024101711145708000_7.3.00321-2021.4","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0845-5"},{"key":"2024101711145708000_7.3.00321-2021.5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711145708000_7.3.00321-2021.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397"},{"key":"2024101711145708000_7.3.00321-2021.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.09.005"},{"key":"2024101711145708000_7.3.00321-2021.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00152609"},{"key":"2024101711145708000_7.3.00321-2021.9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.resinv.2017.09.004","article-title":"Physical activity in daily life in patients with idiopathic pulmonary fibrosis","volume":"56","author":"Nishiyama","year":"2018","journal-title":"Respir Investig"},{"key":"2024101711145708000_7.3.00321-2021.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1634ST"},{"key":"2024101711145708000_7.3.00321-2021.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2007.01205.x"},{"key":"2024101711145708000_7.3.00321-2021.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.088070"},{"key":"2024101711145708000_7.3.00321-2021.13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3390\/jcm9051567","article-title":"Short-term effects of comprehensive pulmonary rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a randomized controlled trial","volume":"9","author":"Jarosch","year":"2020","journal-title":"J Clin Med"},{"key":"2024101711145708000_7.3.00321-2021.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208638"},{"key":"2024101711145708000_7.3.00321-2021.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-015-9703-0"},{"key":"2024101711145708000_7.3.00321-2021.16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12931-018-0884-y","article-title":"Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial","volume":"19","author":"Perez-Bogerd","year":"2018","journal-title":"Respir Res"},{"key":"2024101711145708000_7.3.00321-2021.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024101711145708000_7.3.00321-2021.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024101711145708000_7.3.00321-2021.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(02)00242-8"},{"key":"2024101711145708000_7.3.00321-2021.20","first-page":"A4280","article-title":"Long-term effect of pulmonary rehabilitation under nintedanib treatment in idiopathic pulmonary fibrosis: methodology of the fitness study","volume":"195","author":"Kondoh","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711145708000_7.3.00321-2021.21","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1987.135.6.1229"},{"key":"2024101711145708000_7.3.00321-2021.22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2024101711145708000_7.3.00321-2021.23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2024101711145708000_7.3.00321-2021.24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/resp.12936","article-title":"COPD Assessment Test for measurement of health status in patients with idiopathic pulmonary fibrosis: a cross-sectional study","volume":"22","author":"Matsuda","year":"2017","journal-title":"Respirology"},{"key":"2024101711145708000_7.3.00321-2021.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"2024101711145708000_7.3.00321-2021.26","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.118521"},{"key":"2024101711145708000_7.3.00321-2021.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2024101711145708000_7.3.00321-2021.28","doi-asserted-by":"crossref","unstructured":"Dowman L , Hill CJ , Holland AE . Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10: CD006322.","DOI":"10.1002\/14651858.CD006322.pub3"},{"key":"2024101711145708000_7.3.00321-2021.29","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201604-267OC","article-title":"High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. Methodology of the HOPE-IPF Study","volume":"13","author":"Ryerson","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2024101711145708000_7.3.00321-2021.30","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02674"},{"key":"2024101711145708000_7.3.00321-2021.31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1440-1843.2011.02029.x","article-title":"Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis","volume":"16","author":"Kozu","year":"2011","journal-title":"Respirology"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00321-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:11:07Z","timestamp":1740373867000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00321-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,8,23]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1183\/23120541.00321-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00321-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}